Citidaron - Consilient Health

Introducing
CITIDARON The burden
of smoking The need for
effective cessation Prescribing
information Back to
main site

CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CITIDARON® is the permanent cessation of the nicotine containing products use.

Adverse Events / Product Complaints or for
Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760

Healthcare professionals are asked to report any suspected adverse reactions. To report an adverse event or a product complaint about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or 012057766. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting form and information can be found at http://www.hpra.ie then click on “report an issue”.

IE-CH-1438(2) Date of Preparation April 2024

You are now leaving consilienthealth.ie